X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-13-06-00-00-2625367
https://www.prnewswire.com/news-releases/provention-bio-announces-closing-of-second-tranche-with-hercules-capital-to-support-us-commercial-launch-of-tzield-301737909.html
https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come
https://www.contractpharma.com/contents/view_breaking-news/2022-12-13/almac-pharma-services-supports-launch-of-provention-bios-tzield/?widget=listSection
https://www.globenewswire.com//news-release/2022/11/22/2561000/0/en/JDRF-and-its-affiliates-celebrate-Teplizumab-approval.html
https://www.biopharmadive.com/news/provention-bio-fda-approval-tzield-diabetes/636931/
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-greenlights-provention-bios-diabetes-drug-2022-11-17/
https://www.prnewswire.com/news-releases/fda-approves-first-drug-that-can-delay-onset-of-type-1-diabetes-301682219.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761183
https://www.fiercepharma.com/pharma/proventions-regulatory-odyssey-diabetes-nears-its-end-company-taps-sanofi-marketing-assist
https://www.fiercebiotech.com/biotech/fda-delays-review-provention-bios-embattled-diabetes-prevention-med-new-information-emerges
https://www.prnewswire.com/news-releases/provention-bio-announces-extension-of-fda-user-fee-goal-date-for-teplizumab-to-november-17-2022-301579153.html
https://www.prnewswire.com/news-releases/provention-bio-to-host-a-may-19-2022-virtual-investor-event-focused-on-the-potential-commercial-launch-of-teplizumab-later-this-year-301545693.html
https://www.prnewswire.com/news-releases/provention-bio-announces-fda-acceptance-of-the-biologics-license-application-bla--resubmission-for-teplizumab-for-the-delay-of-clinical-type-1-diabetes-in-at-risk-individuals-301506191.html
https://www.prnewswire.com/news-releases/provention-bio-announces-biologics-license-application-bla-resubmission-for-teplizumab-to-address-complete-response-letter-crl-301487021.html
https://www.fiercebiotech.com/biotech/provention-bio-hires-third-exec-as-many-weeks-as-it-awaits-fda-meeting-for-rejected-drug
https://www.fiercebiotech.com/biotech/provention-bio-hit-by-adcomm-rejection-for-lead-drug-hires-new-early-research-exec-from
https://www.prnewswire.com/news-releases/provention-bio-receives-complete-response-letter-crl-to-biologics-license-application-bla-for-teplizumab-for-the-delay-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals-301325697.html
https://www.prnewswire.com/news-releases/provention-bio-receives-complete-response-letter-crl-to-biologics-license-application-bla-for-teplizumab-for-the-delay-of-clinical-type-1-diabetes-t1d-in-at-risk-individuals-301325697.html
https://endpts.com/news-briefing-10-years-later-teplizumab-gets-a-second-shot-at-an-fda-ok-jj-files-for-amivantamab-approval-in-europe/
https://www.prnewswire.com/news-releases/provention-bio-announces-us-fda-filing-of-a-biologics-license-application-bla-and-priority-review-for-teplizumab-for-the-delay-or-prevention-of-clinical-type-1-diabetes-in-at-risk-individuals-301199992.html
https://www.prnewswire.com/news-releases/provention-bio-completes-rolling-submission-of-the-biologics-license-application-bla-for-teplizumab-for-the-delay-or-prevention-of-clinical-type-1-diabetes-in-at-risk-individuals-301164516.html
https://seekingalpha.com/news/3618602-provention-bio-advances-u-s-marketing-application-for-t1d-med-teplizumab
https://www.prnewswire.com/news-releases/provention-bio-files-clinical-module-for-teplizumab-for-the-delay-or-prevention-of-clinical-type-1-diabetes-in-at-risk-individuals-301142279.html
https://www.prnewswire.com/news-releases/agc-biologics-completes-ppq-manufacturing-campaign-with-provention-bio-for-type-1-diabetes-product-candidate-teplizumab-301117248.html
https://www.prnewswire.com/news-releases/provention-bios-teplizumab-continued-to-significantly-delay-the-onset-of-insulin-dependent-type-1-diabetes-t1d-in-presymptomatic-patients-301076939.html
http://investors.proventionbio.com/2020-06-15-Provention-Bios-Teplizumab-Continued-to-Significantly-Delay-the-Onset-of-Insulin-Dependent-Type-1-Diabetes-T1D-in-Presymptomatic-Patients
https://www.pharmaceutical-business-review.com/contractors/porton-biopharma/news/porton-biopharma-limited-licenses-erwinase-to-clinigen/
https://www.prnewswire.com/news-releases/provention-bio-initiates-rolling-submission-of-biologic-license-application-for-teplizumab-for-the-delay-or-prevention-of-clinical-type-1-diabetes-in-at-risk-individuals-301041624.html
https://endpts.com/jj-drops-its-option-on-provention-bio-drug-after-trial-failure/
https://endpts.com/provention-bios-diabetes-drug-gains-prime-status-avrobio-earns-orphan-status/
https://www.prnewswire.com/news-releases/provention-bio-announces-prv-031-teplizumab-granted-prime-designation-by-the-european-medicines-agency-300944591.html
https://endpts.com/we-kept-at-it-jeffrey-bluestone-plots-late-stage-comeback-after-teplizumab-shown-to-delay-type-1-diabetes/
https://endpts.com/after-a-33-year-odyssey-jeffrey-bluestone-grabs-a-ringside-seat-to-watch-his-drug-teplizumab-go-back-into-the-clinic/
Market Place
Share 
